Pulmatrix (PULM) Expected to Post Quarterly Earnings on Thursday

Pulmatrix (NASDAQ:PULM) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($2.00) per share and revenue of $1.53 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Pulmatrix Stock Performance

NASDAQ:PULM opened at $1.42 on Tuesday. The firm has a market cap of $5.17 million, a price-to-earnings ratio of -1.29 and a beta of 1.93. The firm has a 50-day moving average price of $1.48 and a two-hundred day moving average price of $1.72. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $4.99.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other diseases. The company’s research is based on its iSPERSE dry-powder delivery technology, which is designed to enable efficient administration of pharmaceutical compounds directly to the lungs.

Pulmatrix’s pipeline has included PUR1900, an inhaled formulation of itraconazole being developed for respiratory fungal infections, including allergic bronchopulmonary aspergillosis.